Skip to main content
59°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Olema Oncology
< Previous
1
2
Next >
Olema Oncology to Participate in Upcoming Investor Conferences
September 06, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 05, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Combined Financing for Up to $180 Million
September 05, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 01, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Present at the 2023 Jefferies Healthcare Conference
May 30, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study
May 11, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 09, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress
May 08, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference
April 13, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update
March 09, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 02, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference
March 02, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate at Upcoming Investor Conferences
February 21, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study
December 07, 2022
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2022
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Poster Presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS)
November 21, 2022
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 08, 2022
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2022
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Present at Upcoming Investor Conferences in November
November 01, 2022
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1/2 Clinical Trial
October 26, 2022
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Upcoming Clinical Data Poster Presentation at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 12, 2022
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.